Courts Rule On GLP-1 Shortage Row, 340B In Colo. And More
A Fifth Circuit panel concluded that the U.S. Food and Drug Administration did not unlawfully remove blockbuster GLP-1 medications made by Eli Lilly & Co. and Novo Nordisk from the national...To view the full article, register now.
Already a subscriber? Click here to view full article